Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.

Santra S, Seaman MS, Xu L, Barouch DH, Lord CI, Lifton MA, Gorgone DA, Beaudry KR, Svehla K, Welcher B, Chakrabarti BK, Huang Y, Yang ZY, Mascola JR, Nabel GJ, Letvin NL.

J Virol. 2005 May;79(10):6516-22.

2.

Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.

Paris RM, Kim JH, Robb ML, Michael NL.

Expert Rev Vaccines. 2010 Sep;9(9):1055-69. doi: 10.1586/erv.10.106. Review.

PMID:
20822348
3.

Prospects for vaccine protection against HIV-1 infection and AIDS.

Letvin NL, Barouch DH, Montefiori DC.

Annu Rev Immunol. 2002;20:73-99. Epub 2001 Oct 4. Review.

PMID:
11861598
4.

Adenoviral vectors for mucosal vaccination against infectious diseases.

Santosuosso M, McCormick S, Xing Z.

Viral Immunol. 2005;18(2):283-91. Review.

PMID:
16035940
5.

Novel vaccine vectors for HIV-1.

Barouch DH, Picker LJ.

Nat Rev Microbiol. 2014 Nov;12(11):765-71. doi: 10.1038/nrmicro3360. Epub 2014 Oct 8. Review.

6.
7.

The "STEP-wise" future of adenovirus-based HIV vaccines.

Patterson LJ.

Curr Med Chem. 2011;18(26):3981-6. Review.

PMID:
21824093
8.

Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what's important?.

Fausther-Bovendo H, Kobinger GP.

Hum Vaccin Immunother. 2014;10(10):2875-84. doi: 10.4161/hv.29594. Review.

9.

Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials.

Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A.

Expert Rev Vaccines. 2013 Apr;12(4):379-93. doi: 10.1586/erv.13.15. Review.

PMID:
23560919
10.

DNA vaccines: immunology, application, and optimization*.

Gurunathan S, Klinman DM, Seder RA.

Annu Rev Immunol. 2000;18:927-74. Review.

PMID:
10837079
11.

Adenovirus-based genetic vaccines for biodefense.

Boyer JL, Kobinger G, Wilson JM, Crystal RG.

Hum Gene Ther. 2005 Feb;16(2):157-68. Review.

PMID:
15761256
12.

Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs.

Alonso-Padilla J, Papp T, Kaján GL, Benkő M, Havenga M, Lemckert A, Harrach B, Baker AH.

Mol Ther. 2016 Feb;24(1):6-16. doi: 10.1038/mt.2015.194. Epub 2015 Oct 19. Review.

13.

A new link between virus cell entry and inflammation: adenovirus interaction with integrins induces specific proinflammatory responses.

Nemerow GR.

Mol Ther. 2009 Sep;17(9):1490-1. doi: 10.1038/mt.2009.177. Review. No abstract available.

14.

New viral vectors for HIV vaccine delivery.

Cairns JS, Sarver N.

AIDS Res Hum Retroviruses. 1998 Nov 20;14(17):1501-8. Review. No abstract available.

PMID:
9840283
15.

Viral vectors as vaccine platforms: from immunogenicity to impact.

Ewer KJ, Lambe T, Rollier CS, Spencer AJ, Hill AV, Dorrell L.

Curr Opin Immunol. 2016 Aug;41:47-54. doi: 10.1016/j.coi.2016.05.014. Epub 2016 Jun 7. Review.

PMID:
27286566
16.

Vaccination against pathogenic cells by DNA inoculation.

Wang B, Godillot AP, Madaio MP, Weiner DB, Williams WV.

Curr Top Microbiol Immunol. 1998;226:21-35. Review. No abstract available.

PMID:
9479833

Supplemental Content

Support Center